National Cancer Institute®
Last Modified: January 1, 2002
UI - 11675521
AU - Hounshell J; Tomori C; Newlin R; Knox K; Rundhaugen L; Tallman M;
TI - Bennett C Changes in finances, insurance, employment, and lifestyle among persons diagnosed with hairy cell leukemia.
SO - Oncologist 2001;6(5):435-40
AD - VA Chicago Health Care System-Lakeside Division, Chicago, Illinois 60611, USA.
BACKGROUND: While being cured of cancer generally leads to a life expectancy similar to that of the general population, the extent to which other aspects of life are affected is unknown. To address these concerns, patients with hairy cell leukemia, a cancer with a very high cure rate, were queried about employment, insurance, finances, and lifestyle during and following their treatment. METHODS: Study participants (n = 31) ranging in age from 24 to 73 years at the time of diagnosis (median, 49 years) were surveyed regarding changes in health and life insurance, employment, out-of-pocket medical costs, exercise, diet, and use of mental and alternative health services that occurred during or following hairy cell leukemia treatment. RESULTS: Following a diagnosis of hairy cell leukemia, 61.3% of the respondents paid for some aspect of medical care in spite of having health insurance coverage at the time of diagnosis. Four respondents (12.9%) could not obtain health insurance following treatment, and the occupational choices of several individuals or their spouses were based in large part on a desire to obtain or maintain comprehensive health insurance. Of the 13 individuals who attempted to purchase life insurance, 10 had difficulty obtaining a policy or were denied coverage. Lifestyle changes were noted by 40% to 60% of respondents, and included reports of more frequent exercise, adoption of a healthier diet, and having a greater appreciation for life, loved ones, and physical health. CONCLUSIONS: While hairy cell leukemia is a highly curable malignancy, cancer survivors' lives and lifestyles are altered substantially after receiving treatment for the illness.
UI - 11713166
AU - Konstantinov IE; Zehr KJ
TI - Aortic root replacement in a patient with vancomycin-resistant Enterococcus faecium endocarditis and leukemia.
SO - Chest 2001 Nov;120(5):1744-6
AD - Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN 55902, USA.
Vancomycin-resistant Enterococcus faecium endocarditis is rare and usually occurs in immunocompromised patients. We describe a patient with hairy-cell leukemia and vancomycin-resistant E faecium endocarditis. The patient presented with severe aortic insufficiency. He underwent aortic root replacement with a cryopreserved aortic homograft and was treated with a combination of quinupristin/dalfopristin, ampicillin, and gentamicin.
UI - 11737252
AU - Colovic MD; Jankovic GM; Wiernik PH
TI - Hairy cell leukemia in first cousins and review of the literature.
SO - Eur J Haematol 2001 Sep;67(3):185-8
AD - Institute of Hematology, University Clinical Center, Belgrade, Serbia, Yugoslavia. marcolov@EUnet.yu
Familial hairy cell leukemia (HCL) occurs rarely. So far, 26 familial instances of HCL (in 12 families) have been reported in the literature. The consistent human leukocyte antigen (HLA) linkage could not be established in most cases of familial HCL. History of exposure to organic chemicals or employment in woodworking or farming was noted in only two out of 11 affected families. We present two familial cases of HCL as well as a thorough literature review. An influence of HLA or farming themselves on a predisposition to HCL remains unproven but does not rule out an HLA-linked and as yet unidentified gene responsible for increased disease susceptibility. HCL in families is unlikely to be due to random patterning, but there are insufficient data so far to decisively incriminate either HLA-related or environmental causative factors.
UI - 11736943
AU - Hagberg H; Lundholm L
TI - Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia.
SO - Br J Haematol 2001 Dec;115(3):609-11
AD - Department of Oncology, Akademiska sjukhuset, Uppsala, Sweden. email@example.com
The introduction of first alpha-interferon and later the purine analogues has revolutionized the treatment of hairy cell leukaemia (HCL). However, there are still some patients that initially or eventually fail to respond and, thus, there is a need for alternative treatment modalities. We have treated 11 HCL patients (eight relapsing and three newly diagnosed) with a chimaeric monoclonal antibody, rituximab, in a dose of 375 mg/m2 once a week for 4 weeks. The response rate was seven out of eleven (64%) with six complete remissions and one partial remission, all which have lasted between 0 and 34 months (median 14 months). Rituximab appears promising in the treatment of HCL and warrants further studies.
UI - 3485222
AU - Brito-Babapulle V; Pittman S; Melo JV; Parreira L; Catovsky D
TI - The 14q+ marker in hairy cell leukaemia. A cytogenetic study of 15 cases.
SO - Leuk Res 1986;10(2):131-8
Leukaemic cells from 19 patients with hairy cell leukaemia (HCL), characterised by morphological, immunological and ultrastructural criteria, were investigated for chromosome abnormalities after stimulation with B-cell mitogens (Pokeweed mitogen (PWM), lipopolysaccharide B and EBV). The cells from all cases had a B-cell phenotype and in each case only a single light chain type was expressed on the membrane of the cells. Only 15 patients with adequate metaphases are included in this study. Clonal chromosome abnormalities were observed in 12 patients of which five had a 14q + involving q32. Of the remaining 3 cases 1 had nonclonal abnormalities and 2 had normal karyotypes. The donor chromosomes were identified in 3 cases and were found to be 9, 18 and 22. An interstitial rearrangement of chromosome 14 involving band q22 was seen in 2 cases and a deletion of chromosome 14 at q24 in 1 case. Amongst other chromosome abnormalities 12p was involved in 4 cases, 12q in 2 cases and chromosomes 7 and 22 in 3 cases each. The significance of the abnormalities has been discussed in relation to sites of cellular oncogenes. Our study demonstrates that chromosome abnormalities common to other B-cell disorders are present in HCL.
UI - 3578132
AU - Diez Martin JL; Li CY; Banks PM
TI - Blastic variant of hairy-cell leukemia.
SO - Am J Clin Pathol 1987 May;87(5):576-83
Three patients with hairy-cell leukemia presented with an unusual combination of clinical and cytologic features. Clinical manifestations included constitutional symptoms, progressive left upper abdomen discomfort, and lymphadenopathy. All three had pancytopenia. Bone marrow aspirate was hypercellular, with extensive replacement by abnormal blastic mononuclear cells with a high nuclear/cytoplasmic ratio. Round, oval, or indented nuclei, with reticular chromatin and prominent nucleoli, and basophilic cytoplasm, with abundant large azurophilic granules, were noted. The bone marrow biopsy specimen showed diffuse involvement in two patients and patchy involvement in one, with absence of fibrosis. The abnormal cells were intensely positive by tartrate-resistant acid phosphatase stain. All of the patients responded well initially to splenectomy. One, who presented with multiple chromosomal abnormalities, had a relatively short survival. The other two are alive. One started therapy with chlorambucil 21 months after operation, and the other presented in a hyperleukocytotic phase five years after operation and responded dramatically to 2'-deoxycoformycin.
UI - 6883301
AU - Sadamori N; Han T; Kakati S; Sandberg AA
TI - Chromosomes and causation of human cancer and leukemia. LI. A hairy cell leukemia case with 14q+ and ring chromosomes: significance of ring chromosomes in blood disorders.
SO - Cancer Genet Cytogenet 1983 Sep;10(1):67-77
What appears to be the first hairy cell leukemia case with a 14q+ anomaly is described. In addition to the 14q+ anomaly, a 6q- and a ring chromosome were seen in a blood sample stimulated with lipopolysaccharide, a B-cell mitogen. The clinical course of the present case was short, stormy, and had a poor response to therapy. The correlation between the clinical course and the presence of a ring chromosome in myelo- and lymphoproliferative blood disorders is discussed in relation to the various blood disorders with this karyotype anomaly described in the literature.
UI - 6677564
AU - Ueshima Y; Alimena G; Rowley JD; Golomb HM
TI - Cytogenetic studies in patients with hairy cell leukemia.
SO - Hematol Oncol 1983 Jul-Sep;1(3):215-26
We performed cytogenetic studies on 58 patients with hairy cell leukemia (HCL) from 1975 to 1981. Analysable metaphase cells stained with Q-banding were obtained in 77 samples from 44 patients. Cells with abnormal chromosomes were found in both unstimulated and stimulated cultures of bone marrow and peripheral blood. Patients were classified in 6 groups. Group I, 2 patients with a clonal chromosome abnormality; group II, 13 patients with nonclonal structural abnormalities; group III, 5 patients with nonclonal numerical abnormalities; group IV, 19 patients with only a normal karyotype; group V, 15 patients with no or with fewer than 5 normal metaphase cells; group VI, 4 patients with questionable abnormal chromosomes. Common abnormalities were deletion of the long arm of No. 6 or +3 each in 3 patients, and +Y, +12 or +18 in 2 patients. Actuarial survival for each group was calculated from diagnosis and also from chromosome examination. The two patients with a clonal chromosome abnormality died within one year. Eight of 13 patients with nonclonal structural abnormalities died within 5 years after diagnosis, while none of 5 patients with nonclonal numerical abnormalities and 2 of 19 patients with normal chromosomes died within 5 years. The difference in the 5-year actuarial survival between patients with nonclonal abnormalities (groups II and III) and those with a normal karyotype was significant (p less than 0.05). The difference was more marked between patients with nonclonal structural abnormalities and those with a normal karyotype (p less than 0.01). Patients with nonclonal numerical abnormalities had a longer survival than those patients with nonclonal structural abnormalities (p less than 0.05). Thus, structural chromosome abnormalities in HCL may be a poor prognostic sign even when they are not clonal.
UI - 7719244
AU - Foon KA
TI - Chronic lymphoid leukemias: recent advances in biology and therapy.
SO - Stem Cells 1995 Jan;13(1):1-21
AD - Lucille Parker Markey Cancer Center, Department of Internal Medicine, University of Kentucky Medical Center, Lexington 40536-0093, USA.
There exists a wide variety of lymphoid leukemias derived from B and T lymphocytes. These diseases have distinct immunologic and biologic features as well as varied responses to therapeutics. The most common lymphoid leukemia is chronic lymphocytic leukemia (CLL) which is a clonal proliferation of a subset of B cells expressing the CD5 antigen. Prolymphocytic leukemia is usually derived from B cells and shares some features with CLL but is clearly a distinct entity. Hairy-cell leukemia is a B cell malignancy that is uniquely responsive to a variety of biologic and chemotherapeutic agents. Waldenstrom's macroglobulinemia is a B cell malignancy that secretes immunoglobulin M (IgM) and may present with the hyperviscosity syndrome. Other B cell malignancies that less commonly present as leukemias include non-Hodgkin's lymphomas such as follicular lymphoma or mantle zone lymphoma. Multiple myeloma may rarely present or evolve into a plasma cell leukemia, typically in far advanced disease. T cell malignancies that may present as chronic lymphoid leukemias, and in the past have often been referred to as T cell chronic lymphocytic leukemia, are large granular lymphocytic leukemia, adult T cell leukemia/lymphoma, Sezary cell leukemia and rare cases of non-Hodgkin's lymphoma that are T cell derived and may present or evolve into a leukemic phase. There is also a rare T cell counterpart of prolymphocytic leukemia. Distinguishing these diseases is critical for optimal care of these patients.
UI - 11566344
AU - Sambani C; Trafalis DT; Mitsoulis-Mentzikoff C; Poulakidas E;
TI - Makropoulos V; Pantelias GE; Mecucci C Clonal chromosome rearrangements in hairy cell leukemia: personal experience and review of literature.
SO - Cancer Genet Cytogenet 2001 Sep;129(2):138-44
AD - Laboratory of Health Physics & Environmental Hygiene, I/NT-RP, NCSR "Demokritos," 153 10 Aghia Paraskevi, Athens, Greece. firstname.lastname@example.org
Cytogenetic studies in hairy cell leukemia (HCL) are rare. In the present report, cytogenetic investigations were performed on marrow cells obtained from 21 HCL male patients with a mean age of 57 years and active disease. Karyotypic analysis was successful in 18 of the 21 patients, either at diagnosis or in relapse after treatment with IFNa. Clonal chromosome abnormalities were detected in eight of 18 cases. The chromosome most frequently involved in the rearranged karyotypes was chromosome 14. Results are discussed with respect to 79 abnormal HCL cases obtained from an extensive review of the literature from 1978 to 2000.
UI - 11780695
AU - Heyman MR; Brown LA
TI - A 66-year-old man with hepatosplenomegaly and pancytopenia.
SO - Am J Med Sci 2001 Dec;322(6):365-8
AD - Department of Medicine, University of Maryland School of Medicine, Baltimore, USA.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.